EUSA Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Hemel Hempstead United Kingdom (2005)
Status: Acquired by Jazz Pharmaceuticals (2012)

Organization Overview

First Clinical Trial
2008
NCT00670696
First Marketed Drug
2011
erwinia asparaginase (Erwinaze)
First NDA Approval
2011
erwinia asparaginase (Erwinaze)
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

EUSA Pharma | EUSA Pharma, Inc. | EusaPharma (UK) Limited | EUSA Pharma (UK) Limited | EUSA SAS

Indications

Approved Indications


 

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 3)

Lung Diseases (Phase 3)

Neoplasms (Phase 1)

Respiratory Distress Syndrome (Phase 3)

Respiratory Distress Syndrome, Newborn (Phase 3)

Respiratory Tract Diseases (Phase 3)

Respiratory Tract Infections (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 14
  • # of Trial APIs: 17